Pain relief and improved functional scores (reduced limp, easier stair climbing, longer walking tolerance) occur in 60–75% of treated participants within 3–6 months. Radiographic cartilage thickening or preservation of joint space is observed in approximately 40–50% of cases on follow-up imaging. Successful outcomes are more common in early-stage OA (Kellgren-Lawrence grade 2) than in severe disease.
Twelve completed trials and 3 actively recruiting trials are registered for hip osteoarthritis cell therapy, predominantly using placental MSC or chondrocyte injection into the hip joint under fluoroscopic guidance. Trial cohorts span mild-to-moderate radiographic OA (Kellgren-Lawrence grades 2–3) and include both primary OA and post-traumatic arthritis. Cartilage imaging by MRI has shown improved signal intensity (suggesting rehydrated cartilage matrix) in 40–60% of treated hips at 12 months. Pain scores and functional metrics (6-minute walk distance, Harris Hip Score) improve modestly in 55–75% of participants over 6–24 months, though comparative data versus placebo injection are sparse.
Съм ли кандидат? → · Hip Osteoarthritis: full overview → · Цена Артроза на тазобедрото → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка